MidWestOne Financial Group Inc. Raises Holdings in United Therapeutics Corporation $UTHR

MidWestOne Financial Group Inc. raised its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 741.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,446 shares of the biotechnology company’s stock after purchasing an additional 8,324 shares during the quarter. MidWestOne Financial Group Inc.’s holdings in United Therapeutics were worth $3,960,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Bessemer Group Inc. increased its position in shares of United Therapeutics by 2.6% during the 3rd quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock worth $472,000 after purchasing an additional 28 shares during the last quarter. Archer Investment Corp boosted its stake in United Therapeutics by 9.5% during the third quarter. Archer Investment Corp now owns 356 shares of the biotechnology company’s stock worth $149,000 after buying an additional 31 shares during the period. F m Investments LLC increased its position in shares of United Therapeutics by 1.3% during the second quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock valued at $741,000 after acquiring an additional 33 shares during the last quarter. WealthCollab LLC lifted its holdings in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the last quarter. Finally, Coldstream Capital Management Inc. lifted its holdings in shares of United Therapeutics by 2.0% in the 2nd quarter. Coldstream Capital Management Inc. now owns 2,145 shares of the biotechnology company’s stock worth $616,000 after acquiring an additional 43 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on UTHR shares. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. HC Wainwright lifted their price objective on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Royal Bank Of Canada boosted their price objective on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. Morgan Stanley set a $447.00 target price on United Therapeutics in a report on Wednesday, October 29th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $575.00 price target on shares of United Therapeutics in a research note on Wednesday, November 19th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $509.50.

United Therapeutics Price Performance

UTHR stock opened at $473.66 on Friday. The business’s 50-day moving average is $486.02 and its two-hundred day moving average is $432.54. The firm has a market capitalization of $20.40 billion, a P/E ratio of 17.95, a P/E/G ratio of 2.53 and a beta of 0.85. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $519.99.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $470.43, for a total transaction of $10,584,675.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 502,214 shares of company stock valued at $242,241,993 in the last ninety days. 10.30% of the stock is owned by insiders.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.